IL6 and Sepsis: Since the combined sensitivity and specificity of actual biomarkers (e.g., CPR, PCT, IL-6, etc.)do not allow for the rapid ascertainment of the diagnosis [14,15], they cannot always discriminate early enough between infectious and non-infectious patients and rapidly evolving patients from the more stable ones, whilst sepsis-related adverse outcomes rise with every hour of delay of proper intervention; new early biomarkers are urgently needed.